Meeting
2018 ASCO Annual Meeting
Selection for Oncotype Dx testing among young women with early-stage ER+/HER2- breast cancer.
Authors
Philip Daniel Poorvu
Dana-Farber Cancer Institute, Boston, MA
Philip Daniel Poorvu , Shari I. Gelber , Shoshana M. Rosenberg , Kathryn Jean Ruddy , Rulla Tamimi , Jeffrey M. Peppercorn , Lidia Schapira , Virginia F. Borges , Steven E. Come , Laura C. Collins , Ellen Warner , Ann H. Partridge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 533)
DOI
10.1200/JCO.2018.36.15_suppl.533
Abstract #
533
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
First Author: Erika P. Hamilton
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei
Poster
2017 ASCO Annual Meeting
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
First Author: Nusayba Ali Bagegni
Poster
2016 ASCO Annual Meeting
A Phase 1 study of RAD1901, an oral selective estrogen receptor degrader, in ER positive, HER2 negative, advanced breast cancer patients.
First Author: Elisabeth De Vries